Global Tumor Genomics Market

      2.1   Scope of the Study
      2.2   Key Questions Answered in the Report

      3.1   Global Tumor Genomics: Research Methodology
      3.2   Primary Data Sources
      3.3   Secondary data sources
      3.4   Data Triangulation
      3.5   Segmentation of the Global Tumor Genomics Market
      3.6   Inclusion and Exclusion
      3.7   Base Year and Forecast Year

      4.1   Market Overview
      4.2   Introduction to Tumor Genomics
      4.3   Evolution of Tumor Genomic Techniques
      4.4   Global Market Scenario and Key Technology Trends

      5.1   Introduction
      5.2   Impact Analysis
      5.3   Market Drivers
              5.3.1   Rising Government Initiatives and Projects
              5.3.2   Increasing Incidence of Cancer
              5.3.3   Increasing Number of Product Approval and Launches
              5.3.4   Ever Expanding Application Areas for Genomics
              5.3.5   Increasing Use of Biomarkers in Cancer Profiling
      5.4   Market Restraints
              5.4.1   High Cost of Genomic Equipment
              5.4.2   Lack of Unified Framework for Data Integration
      5.5   Market Opportunities
              5.5.1   Growing Prominence for Precision Medicine
              5.5.2   Increasing Demand for Point-of-Care Diagnostics

      6.1   Regulatory Requirements
              6.1.1   Regulatory Framework in the U.S.
                         6.1.1.1   Guidelines Published in FY2018
                         6.1.1.2   Guidelines Published in FY2016
              6.1.2   Europe
              6.1.3   Japan
      6.2   Patent Analysis

      7.1   Key Developments and Strategies
              7.1.1   Partnerships and Alliances
              7.1.2   New Product Launches
              7.1.3   Mergers and Acquisition Activities
              7.1.4   Business Expansions
              7.1.5   Others
      7.2   Market Share Analysis
              7.2.1   Market Share Analysis (by Company)
      7.3   Growth Share Analysis
              7.3.1   Growth Share Matrix (by Company)

      8.1   Assays and Kits
      8.2   Instrument

      9.1   Next Generation Sequencing (NGS)
      9.2   Polymerase Chain Reaction (PCR)
      9.3   Microarray
      9.4   In-Situ Hybridization (ISH)
      9.5   Immunohistochemistry (IHC)
      9.6   Other Technologies (Mass Spectrometry and Flow Cytometry)

        10.1   Diagnostics and Monitoring
        10.2   Drug Discovery and Development
        10.3   Biomarker Discovery

        11.1   Academics and Research Organizations
        11.2   Hospitals and Ambulatory Clinics
        11.3   Clinical and Diagnostic Laboratories
        11.4   Biotechnology and Pharmaceutical Companies

        12.1   Leukemia
        12.2   Breast Cancer
        12.3   Melanoma
        12.4   Colon Cancer
        12.5   Lung Cancer
        12.6   Prostate Cancer
        12.7   Head and Neck Cancer
        12.8   Others (Ovarian, Pancreatic, and Testicular)

        13.1   North America
                  13.1.1   North America Tumor Genomics Market (by Country)
                  13.1.2   U.S.
                  13.1.3   Canada
        13.2   Europe
                  13.2.1   Europe Tumor Genomics Market (by Country)
                  13.2.2   Germany
                  13.2.3   U.K.
                  13.2.4   France
                  13.2.5   Italy
                  13.2.6   Spain
                  13.2.7   Netherlands
                  13.2.8   Rest-of-Europe
         13.3   Asia-Pacific (APAC)
                  13.3.1   Asia-Pacific Tumor Genomics Market (by Country)
                  13.3.2   China
                  13.3.3   Japan
                  13.3.4   Australia
                  13.3.5   India
                  13.3.6   Rest-of-Asia-Pacific
        13.4   Rest-of-the-World
                  13.4.1   Rest-of-the-World Tumor Genomics Market (by Country)
                  13.4.2   Latin America
                  13.4.3   Middle East & Africa

        14.1   Abbott Laboratories
                  14.1.1   Company Overview
                  14.1.2   Role of Abbott Laboratories in the Global Tumor Genomics Market
                  14.1.3   Financials
                  14.1.4   Key Insights About Financial Health of the Company
                  14.1.5   SWOT Analysis
         14.2   Agilent Technologies, Inc.
                  14.2.1   Company Overview
                  14.2.2   Role of Agilent Technologies, Inc. in the Global Tumor Genomics Market
                  14.2.3   Financials
                  14.2.4   Key Insights About Financial Health of the Company
                  14.2.5   SWOT Analysis
        14.3   Bio-Rad Laboratories, Inc.
                  14.3.1   Company Overview
                  14.3.2   Role of Bio-Rad Laboratories, Inc. in the Global Tumor Genomics Market
                  14.3.3   Financials
                  14.3.4   Key Insights About Financial Health of the Company
                  14.3.5   SWOT Analysis
        14.4   Danaher Corporation
                  14.4.1   Company Overview
                  14.4.2   Role of Danaher Corporation in the Global Tumor Genomics Market
                  14.4.3   Financials
                  14.4.4   Key Insights About Financial Health of the Company
                  14.4.5   SWOT Analysis
        14.5   F. Hoffmann-La Roche Ltd
                  14.5.1   Company Overview
                  14.5.2   Role of F. Hoffmann-La Roche Ltd in the Global Tumor Genomics Market
                  14.5.3   Financials
                  14.5.4   Key Insights About Financial Health of the Company
                  14.5.5   SWOT Analysis
        14.6   Fluidigm Corporation
                  14.6.1   Company Overview
                  14.6.2   Role of Fluidigm Corporation in the Global Tumor Genomics Market
                  14.6.3   Financials
                  14.6.4   Key Insights About Financial Health of the Company
                  14.6.5   SWOT Analysis
        14.7   General Electric Company
                  14.7.1   Company Overview
                  14.7.2   Role of General Electric Company in the Global Tumor Genomics Market
                  14.7.3   Financials
                  14.7.4   Key Insights About Financial Health of the Company
                  14.7.5   SWOT Analysis
        14.8   Illumina, Inc.
                  14.8.1   Company Overview
                  14.8.2   Role of Illumina, Inc. in the Global Tumor Genomic Market
                  14.8.3   Financials
                  14.8.4   Key Insights About Financial Health of the Company
                  14.8.5   SWOT Analysis
        14.9   Merck KGaA
                  14.9.1   Company Overview
                  14.9.2   Role of Merck KGaA in the Global Tumor Genomics Market
                  14.9.3   Financials
                  14.9.4   Key Insights About Financial Health of the Company
                  14.9.5   SWOT Analysis
      14.10   Myriad Genetics, Inc.
                  14.10.1   Company Overview
                  14.10.2   Role of Myriad Genetics, Inc. in the Global Tumor Genomics Market
                  14.10.3   Financials
                  14.10.4   Key Insights About Financial Health of the Company
                  14.10.5   SWOT Analysis
       14.11   Pacific Biosciences of California, Inc.
                  14.11.1   Company Overview
                  14.11.2   Role of Pacific Biosciences of California, Inc. in the Global Tumor Genomics Market
                  14.11.3   Financials
                  14.11.4   Key Insights About Financial Health of the Company
                  14.11.5   SWOT Analysis
      14.12   PerkinElmer
                  14.12.1   Company Overview
                  14.12.2   Role of PerkinElmer in the Global Tumor Genomics Market
                  14.12.3   Financials
                  14.12.4   Key Insights about Financial Health of the Company
                  14.12.5   SWOT Analysis
      14.13   QIAGEN
                  14.13.1   Company Overview
                  14.13.2   Role of QIAGEN in the Global Tumor Genomics Market
                  14.13.3   Financials
                  14.13.4   Key Insights about Financial Health of the Company
                  14.13.5   SWOT Analysis
      14.14   Siemens Healthineers AG
                  14.14.1   Company Overview
                  14.14.2   Role of Siemens Healthineers AG in the Global Tumor Genomics Market
                  14.14.3   Financials
                  14.14.4   Key Insights about Financial Health of the Company
                  14.14.5   SWOT Analysis
      14.15   Thermo Fisher Scientific Inc.
                  14.15.1   Company Overview
                  14.15.2   Role of Thermo Fisher Scientific Inc. in the Global Tumor Genomics Market
                  14.15.3   Financials
                  14.15.4   Key Insights on the Financial Health of the Company
                  14.15.5   SWOT Analysis

Table 1:    Key Product Launches Between May 2017-February 2020
Table 5.1:    Impact Analysis of Market Drivers
Table 5.2:    Impact analysis of Market Restraints
Table 5.3:    Number of Product Launches (2018-2020)
Table 5.4:    Number of Product Approvals (2018 and 2019)
Table 6.1:    List of Major Regulatory Bodies and Associations across the World
Table 6.2:    Global Tumor Genomics Market: Patent Analysis
Table 8.1:    Competitive Benchmarking by Product and Technique

Figure 1:    Percentage of Cancer Deaths, by Type: 2007-2020
Figure 2:    Global Tumor Genomics Market Value, 2018-2028
Figure 3:    Drivers and Restraints of Global Tumor Genomics Market
Figure 4:    Share of Key Developments and Strategies, January 2017-February 2020
Figure 5:    Global Tumor Genomics Market (by Product), 2018-2028
Figure 6:    Global Tumor Genomics Market (by Technique), 2018-2028
Figure 7:    Global Tumor Genomics Market (by Application), 2018-2028
Figure 8:    Global Tumor Genomics Market (by End User), 2018-2028
Figure 9:    Global Tumor Genomics Market (by Cancer Type), 2018-2028
Figure 10:    Global Tumor Genomics Market (by Region): 2019 and 2028
Figure 3.1:    Global Tumor Genomics Market Research Methodology
Figure 3.2:    Primary Research
Figure 3.3:    Secondary Research
Figure 3.4:    Data Triangulation
Figure 3.5:    Top-Down Approach (Segment-Wise Analysis)
Figure 3.6:    Bottom-up Approach (Segment-Wise Analysis)
Figure 3.7:    Assumptions and Limitations
Figure 3.8:    Assumptions and Limitations
Figure 3.9:    Segmentation of the Global Tumor Genomics Market
Figure 4.1:    Evolution of Tumor Genomic Techniques
Figure 4.2:    Global Tumor Genomics Market Size, 2018-2028
Figure 5.1:    Incidence of Different Cancers (2014-2017)
Figure 7.1:    Competitive Landscape, January 2017-February 2020
Figure 7.2:    Share of Key Developments and Strategies, January 2017-February 2020
Figure 7.3:    Partnerships and Alliances (by Company), January 2017-February 2020
Figure 7.4:    New Product Launches (by Company), January 2017-February 2020
Figure 7.5:    Others (by Company), January 2017-February 2020
Figure 7.6:    Market Share Analysis for the Global Tumor Genomics Market,  by Company (2019)
Figure 7.7:    Growth Share Matrix: Global Tumor Genomics Market (by Company),  2018-2019
Figure 8.1:    Global Tumor Genomics Market (by Product)
Figure 8.2:    Global Tumor Genomics Market (by Product), 2018-2028
Figure 8.3:    Global Tumor Genomics Market for Assays and Kits, 2018-2028
Figure 8.4:    Global Tumor Genomics Market for Instruments, 2018-2028
Figure 9.1:    Global Tumor Genomics Market, by Techniques
Figure 9.2:    Global Tumor Genomics Market (by Technique), 2018-2028
Figure 9.3:    Global Tumor Genomics Market (Technique: Next-Generation Sequencing), 2018-2028
Figure 9.4:    Global Tumor Genomics Market (Technique: Polymerase Chain Reaction), 2018-2028
Figure 9.5:    Global Tumor Genomics Market (Technique: Microarray) , 2018-2028
Figure 9.6:    Global Tumor Genomics Market (Technique: In-Situ Hybridization), 2018-2028
Figure 9.7:    Global Tumor Genomics Market (Technique: Immunohistochemistry),  2018-2028
Figure 9.8:    Global Tumor Genomics Market (Technique: Other Technologies {Mass Spectrometry and Flow Cytometry}), 2018-2028
Figure 10.1:    Global Tumor Genomics Market, by Application
Figure 10.2:    Global Tumor Genomics Market (by Application), 2018-2028
Figure 10.3:    Global Tumor Genomics Market (Application: Diagnostics and Monitoring), 2018-2028
Figure 10.4:    Global Tumor Genomics Market (Application: Drug Discovery and Development), 2018-2028
Figure 10.5:    Global Tumor Genomics Market (Application: Biomarker Discovery),  2018-2028
Figure 11.1:    Global Tumor Genomics Market, by End User
Figure 11.2:    Global Tumor Genomics Market (by End User), 2018-2028
Figure 11.3:    Global Tumor Genomics Market (End User: Academics and Research Organizations), 2018-2028
Figure 11.4:    Global Tumor Genomics Market (End User: Hospitals and Ambulatory Clinics), 2018-2028
Figure 11.5:    Global Tumor Genomics Market (End User: Clinical and Diagnostic Laboratories), 2018-2028
Figure 11.6:    Global Tumor Genomics Market (End User: Biotechnology and Pharmaceutical Company), 2018-2028
Figure 12.1:    Global Tumor Genomics Market, by Cancer Type
Figure 12.2:    Global Tumor Genomics Market (by Cancer Type), 2018-2028
Figure 12.3:    Global Tumor Genomics Market (Cancer Type: Leukemia), 2018-2028
Figure 12.4:    Global Tumor Genomics Market (Cancer Type: Breast Cancer), 2018-2028
Figure 12.5:    Global Tumor Genomics Market (Cancer Type: Melanoma), 2018-2028
Figure 12.6:    Global Tumor Genomics Market (Cancer Type: Colon Cancer), 2018-2028
Figure 12.7:    Global Tumor Genomics Market (Cancer Type: Lung Cancer), 2018-2028
Figure 12.8:    Global Tumor Genomics Market (Cancer Type: Prostate Cancer), 2018-2028
Figure 12.9:    Global Tumor Genomics Market (Cancer Type: Head and Neck Cancer), 2018-2028
Figure 12.10: Global Tumor Genomics Market (Cancer Type: Others {Ovarian, Pancreatic, and Testicular}), 2018-2028    
Figure 13.1:    Global Tumor Genomics Market (by Region), 2019 and 2028
Figure 13.2:    North America Tumor Genomics Market, 2018-2028
Figure 13.3:    North America: Market Dynamics
Figure 13.4:    North America Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.5:    U.S. Tumor Genomics Market, 2018-2028
Figure 13.6:    Canada: Tumor Genomics Market, 2018-2028
Figure 13.7:    Europe: Tumor Genomics Market, 2018-2028
Figure 13.8:    Europe: Market Dynamics
Figure 13.9:    Europe Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.10:    Germany Tumor Genomics Market, 2018-2028
Figure 13.11:    U.K. Tumor Genomics Market, 2018-2028
Figure 13.12:    France Tumor Genomics Market, 2018-2028
Figure 13.13:    Italy Tumor Genomics Market, 2018-2028
Figure 13.14:    Spain Tumor Genomics Market, 2018-2028
Figure 13.15:    Netherlands Tumor Genomics Market, 2018-2028
Figure 13.16:    Rest-of-Europe Tumor Genomics Market, 2018-2028
Figure 13.17:    Asia-Pacific: Tumor Genomics Market, 2018-2028
Figure 13.18:    Asia-Pacific: Market Dynamics
Figure 13.19:    Asia-PacificTumor Genomics Market (by Country), 2019 and 2028
Figure 13.20:    China Tumor Genomics Market, 2018-2028
Figure 13.21:    Japan Tumor Genomics Market, 2018-2028
Figure 13.22:    Australia Tumor Genomics Market, 2018-2028
Figure 13.23:    India Tumor Genomics Market, 2018-2028
Figure 13.24:    Rest-of-Asia-Pacific Tumor Genomics Market, 2018-2028
Figure 13.25:    Rest-of-the-World Tumor Genomics Market, 2018-2028
Figure 13.26:    Rest-of-the-World (RoW): Market Dynamics
Figure 13.27:    Rest-of-the-World Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.28:    Latin America Tumor Genomics Market, 2018-2028
Figure 13.29:    Middle East & Africa Tumor Genomics Market, 2018-2028
Figure 14.1:    Abbott Laboratories: Product Offerings for the Global Tumor Genomics Market
Figure 14.2:    Abbott Laboratories: Overall Financials, 2017-2019
Figure 14.3:    Abbott Laboratories: Revenue (by Product/Service), 2017-2019
Figure 14.4:    Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 14.5:    Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 14.6:    Abbott Laboratories: SWOT Analysis
Figure 14.7:    Agilent Technologies, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.8:    Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.9:    Agilent Technologies, Inc.: Revenue (by Business Model), 2017-2019
Figure 14.10:    Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 14.11:    Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 14.12:    Agilent Technologies, Inc.: SWOT Analysis
Figure 14.13:    Bio-Rad Laboratories, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.14:    Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 14.15:    Bio-Rad Laboratories, Inc.: Revenue (by Product/Service), 2016-2018
Figure 14.16:    Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
Figure 14.17:    Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 14.18:    Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.19:    Danaher Corporation Product Offerings for the Global Tumor  Genomics Market
Figure 14.20:    Danaher Corporation: Overall Financials, 2017-2019
Figure 14.21:    Danaher Corporation: Revenue (by Product/Service), 2017-2019
Figure 14.22:    Danaher Corporation: Revenue (by Region), 2017-2019
Figure 14.23:    Danaher Corporation: R&D Expenditure, 2017-2019
Figure 14.24:    Danaher Corporation: SWOT Analysis
Figure 14.25:    F. Hoffman-La-Roche Ltd: Product Offerings for the Global Tumor Genomics Market
Figure 14.26:    F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 14.27:    F. Hoffmann-La Roche Ltd: Revenue (by Product/Service), 2017-2019
Figure 14.28:    F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 14.29:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2018
Figure 14.30:    F. Hoffmann-La Roche AG: SWOT Analysis
Figure 14.31:    Fluidigm Corporation: Overall Product Portfolio
Figure 14.32:    Fluidigm Corporation: Overall Financials, 2017-2019
Figure 14.33:    Fluidigm Corporation: Revenue (by Business Segment), 2016-2018
Figure 14.34:    Fluidigm Corporation: Revenue (by Region), 2016-2018
Figure 14.35:    Fluidigm Corporation: R&D Expenditure, 2016-2018
Figure 14.36:    Fluidigm Corporation: SWOT Analysis
Figure 14.37:    General Electric Company: Product Offerings for the Global Tumor Genomics Market
Figure 14.38:    General Electric Company: Overall Financials, 2017-2019
Figure 14.39:    General Electric Company: Revenue (by Business Model), 2017-2019
Figure 14.40:    General Electric Company: Revenue (by Region), 2017-2019
Figure 14.41:    General Electric Company: R&D Expenditure, 2017-2019
Figure 14.42:    General Electric Company: SWOT Analysis
Figure 14.43:    Illumina, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.44:    Illumina, Inc.: Overall Financials, 2016-2018
Figure 14.45:    Illumina Inc.: Revenue (by Segment), 2016-2018
Figure 14.46:    Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 14.47:    Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 14.48:    Illumina, Inc.: SWOT Analysis
Figure 14.49:    Merck KGaA: Product Offerings for the Global Tumor Genomics Market
Figure 14.50:    Merck KGaA: Overall Financials, 2017-2019
Figure 14.51:    Merck KGaA: Revenue (by Product/Service), 2017-2019
Figure 14.52:    Merck KGaA: Revenue (by Region), 2017-2019
Figure 14.53:    Merck KGaA: R&D Expenditure, 2017-2019
Figure 14.54:    Merck KGaA: SWOT Analysis
Figure 14.55:    Myriad Genetics, Inc.: Product Offerings for the Global Tumor  Genomics Market
Figure 14.56:    Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 14.57:    Myriad Genetics, Inc.: Revenue (by Product/Service), 2017-2019
Figure 14.58:    Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 14.59:    Myriad Genetics, Inc.: SWOT Analysis
Figure 14.60:    Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 14.61:    Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018
Figure 14.62:    Pacific Biosciences of California, Inc.: Revenue (by Product/Service), 2016-2018
Figure 14.63:    Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018
Figure 14.64:    Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018
Figure 14.65:    Pacific Biosciences: SWOT Analysis
Figure 14.66:    PerkinElmer: Product Offerings for the Global Tumor Genomics Market
Figure 14.67:    Perkin Elmer: Overall Financials, 2017-2019
Figure 14.68:    PerkinElmer: Revenue (by Products & Services), 2017-2019
Figure 14.69:    PerkinElmer: Revenue (by Region), 2017-2019
Figure 14.70:    PerkinElmer: R&D Expenditure, 2017-2019
Figure 14.71:    PerkinElmer lnc.: SWOT Analysis
Figure 14.72:    QIAGEN: Product Offerings for the Global Tumor Genomics Market
Figure 14.73:    QIAGEN: Overall Financials, 2016-2018
Figure 14.74:    QIAGEN: Revenue (by Business Model), 2016-2018
Figure 14.75:    QIAGEN: Revenue (by Region), 2016-2018
Figure 14.76:    QIAGEN: R&D Expenditure, 2016-2018
Figure 14.77:    QIAGEN: SWOT Analysis
Figure 14.78:    Siemens Healthineers AG: Product Offerings for the Global Tumor Genomics Market
Figure 14.79:    Siemens Healthineers AG Overall Financials, 2017-2019
Figure 14.80:    Siemens Healthineers AG: Revenue (by Product and Services), 2017-2019
Figure 14.81:    Siemens Healthineers AG: Revenue (by Region), 2017-2019
Figure 14.82:    Siemens Healthineers AG: R&D Expenditure, 2017-2019
Figure 14.83:    Siemens Healthineers AG: SWOT Analysis
Figure 14.84:    Thermo Fisher Scientific Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.85:    Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 14.86:    Thermo Fisher Scientific Inc.: Net Revenue (by Business Segment),  2017-2019
Figure 14.87:    Thermo Fisher Scientific Inc.: Net Revenue (by Region), 2017-2019
Figure 14.88:    Thermo Fisher Scientific Inc.: R&D Expense, 2017-2019
Figure 14.89:    Thermo Fisher Scientific, Inc.: SWOT Analysis